Today, CB Insights China published, for the first time, a top list of RNA biotech companies in China and Ractigen Therapeutics, as the only company developing RNAa therapeutics, is listed as top 3.

CB Insights is a world-renowned venture capital analysis institution which publishes investment analysis reports in various industries and fields which are adopted by many VCs in their database and think tanks for decision-making.

“RNAa technology will open up a brand new field in pharmaceutical industry with a bright market prospect, if Ractigen’s programs advance smoothly.” said CB Insights.